

Contact No. : 0091-22-4162 6666
E-mail : info@prismile.com
Website : www.prismile.com



10th Floor, 'A' Wing, The Great Eastern Summit,
Sector - 15, CBD Belapur, Navi Mumbai - 400 614,
India.

Drug Facts

COMPOSITION : Each vial contains Ceftriaxone Sodium eq to Ceftriaxone 1 g	PHARMACOLOGICAL CLASS : Antibacterials for systemic use
--	--

NAME : Ceftriaxone For Injection 1 gm

AVAILABLE AS : Ceftriaxone For Injection 1 gm

PHARMACOLOGICAL ACTION : Ceftriaxone inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.

USED FOR : Ceftriaxone is indicated in the treatment of the following infections in adults and children: Bacterial Meningitis, Community acquired pneumonia, Hospital acquired pneumonia, Acute otitis media, Intra-abdominal infections, Complicated urinary tract infections (including pyelonephritis), Infections of bones and joints, Complicated skin and soft tissue infections, Gonorrhoea, Syphilis, Bacterial endocarditis, Also for treatment of acute exacerbations of chronic obstructive pulmonary disease in adults, disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age, Pre-operative prophylaxis of surgical site infections, In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection, In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above, Ceftriaxone should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

SIDE EFFECTS : Loose stools/diarrhoea, nausea, vomiting, stomatitis, glossitis, Eosinophilia, haematoma, thrombocytopenia, neutropenia, leukopenia, granulocytopenia and haemolytic anaemia, Isolated cases of agranulocytosis, Exanthema, allergic dermatitis, pruritus, urticaria, oedema, erythema multiforme may occur.

WARNINGS : Ceftriaxone is contraindicated in Premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age), Full-term neonates (up to 28 days of age): with hyperbilirubinaemia, jaundice, or who are hypoalbuminaemic or acidotic because these are conditions in which bilirubin binding is likely to be impaired, if they require (or are expected to require) intravenous calcium treatment, or calcium-containing infusions due to the risk of precipitation of a ceftriaxone-calcium salt.

OUR ADVICE : DO NOT SELF MEDICATE

The information provided in the LEAFLET is a part of Prism's continuous patient education programme (CPEP). Under no circumstances should Prism be held liable for any loss or damage indirect or consequential due to the use of data. While we endeavour to keep the information up to date and correct, we advise the user of the data to talk to the pharmacist.

This is a computer generated document.

Print Date : 16/07/2020 19:11 PM (IST)